Relapsed or Refractory Hematologic Malignancies
6 clinical trials · Condition
◉ Watch Relapsed or Refractory Hematologic Malignancies
| Record | Firm | Date |
|---|---|---|
| Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies (NCT07485504) | Tcelltech Inc. | 2026-04-15 |
| A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies (NCT07173595) | Qilu Pharmaceutical Co., Ltd. | 2025-12-05 |
| A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies (NCT07107204) | Biotroy Therapeutics | 2025-10-01 |
| A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies (NCT06252298) | Sinocelltech Ltd. | 2024-02-28 |
| Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML) (NCT04926285) | University of Illinois at Chicago | 2022-06-21 |
| Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies (NCT03838926) | Vanda Pharmaceuticals | 2018-09-27 |
Track Relapsed or Refractory Hematologic Malignancies automatically
Every clearance here is in the API, with alerts when new ones post.